Seres director granted 7,508 stock options
Seres Therapeutics director grants stock options Seres Therapeutics, Inc. director Robert L. Rosiello received a grant of stock options covering 7,508 shares of common stock at an exercise price of $7.94 per share.
Rhea-AI Filing Summary
Seres Therapeutics director grants stock options
Seres Therapeutics, Inc. director Robert L. Rosiello received a grant of stock options covering 7,508 shares of common stock at an exercise price of $7.94 per share. These options were awarded as compensation rather than purchased on the open market.
The options vest in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, with the final installment vesting earlier if the 2027 annual stockholder meeting occurs before July 1, 2027, subject to his continued service on the board as a non-employee director.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 7,508 shares
Grant/Award
1 txn
Insider
Rosiello Robert L.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,508 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,508 contracts (Direct)
Footnotes (1)
- F1. The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027, provided that if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date.
Key Figures
Options granted: 7,508 options
Exercise price: $7.94 per share
Post-transaction options held: 7,508 options
+2 more
5 metrics
Options granted
7,508 options
Stock option grant to director Robert L. Rosiello
Exercise price
$7.94 per share
Exercise price of newly granted stock options
Post-transaction options held
7,508 options
Total derivative securities following the grant
Option expiration
July 1, 2036
Expiration date of the stock options
Vesting dates
Oct 1 2026 – Jul 1 2027
Four equal quarterly vesting installments
Key Terms
Stock Option (right to buy), exercise price, vesting, non-employee director, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "7.9400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests and becomes exercisable in four equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
non-employee director financial
"subject to the reporting person continuing in service on the Board as a non-employee director"
annual meeting of stockholders financial
"if the issuer's 2027 annual meeting of stockholders occurs before July 1, 2027"
FAQ
What did Seres Therapeutics (MCRB) director Robert L. Rosiello receive in this Form 4?
Robert L. Rosiello received a grant of stock options for 7,508 shares of Seres Therapeutics common stock. The options carry a $7.94 exercise price and represent compensation as a non-employee director rather than an open-market share purchase.
What is the exercise price of the new Seres Therapeutics (MCRB) stock options?
The granted stock options have an exercise price of $7.94 per share. This means Rosiello can buy Seres Therapeutics common stock at $7.94 once the options vest, regardless of the market price at that time, subject to the vesting schedule.
How do the newly granted Seres Therapeutics (MCRB) options vest for Robert L. Rosiello?
The options vest in four equal quarterly installments on October 1, 2026, January 1, 2027, April 1, 2027, and July 1, 2027. The final installment may vest earlier if the 2027 annual meeting occurs before July 1, 2027, assuming continued board service.
How many Seres Therapeutics (MCRB) derivative securities does Robert L. Rosiello hold after this transaction?
After the transaction, Rosiello holds 7,508 stock options according to the filing’s post-transaction total. These options give him the right to acquire 7,508 shares of Seres Therapeutics common stock once vested and exercised at the stated exercise price.
Is the Seres Therapeutics (MCRB) Form 4 transaction a stock purchase or a compensation grant?
The Form 4 reflects a compensation grant of stock options, not an open-market stock purchase. The transaction uses code A, indicating a grant or award, and carries a zero-dollar transaction price with a separate $7.94 per share exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
